India, often called the “Pharmacy of the World,” supplies over 20% of the global market for generic medicines and exports pharmaceutical products to more than 200 countries. However, for international buyers, navigating the regulatory documentation required to import Indian generic medicines can be complex. This guide explains India’s pharmaceutical export certification system in 2026 — covering CDSCO’s role, WHO-GMP certification, the EU written confirmation process, and practical steps buyers can take to verify that their suppliers meet global regulatory standards.
📜 What Is Pharmaceutical Export Certification?
Pharmaceutical export certification refers to the set of official documents issued by a country’s drug regulatory authority (in India, the Central Drugs Standard Control Organization or CDSCO) that verify a pharmaceutical product and its manufacturer meet the required safety, quality, and efficacy standards for export to another country.
For Indian generic medicine exporters, the key certifications include:
- Certificate of Pharmaceutical Product (COPP) — The most commonly required document, certifying that the product is approved for sale in India and manufactured to GMP standards. COPP is based on the WHO certification scheme and is accepted by over 150 countries.
- WHO-GMP Certificate — Confirms the manufacturing facility complies with WHO Good Manufacturing Practices standards.
- Free Sale Certificate — A declaration that the product is freely sold in India without restriction.
- Written Confirmation (for EU exports) — A formal statement from CDSCO confirming the API manufacturer complies with EU GMP standards equivalent to those in the European Union.
- No Objection Certificate (NOC) for Import/Export — Required for certain controlled substances and narcotic-based medicines.
🏛️ CDSCO’s Expanding Role in Export Certification (2026)
The Central Drugs Standard Control Organization (CDSCO) is India’s national drug regulatory authority. In 2026, CDSCO is undergoing a major transformation aimed at strengthening its credibility on the global stage. As reported by The Pharma Letter (February 2026), CDSCO is charting a “risk-based path to global credibility,” reshaping its oversight model to align with international expectations.
Key developments in CDSCO’s export certification framework in 2026 include:
- Streamlined written confirmation process for API exports to the EU — Under EU law, active pharmaceutical ingredients (APIs) shipped from India and other non-listed countries must be supported by a written confirmation from CDSCO verifying the manufacturer’s GMP compliance. As reported by RAPS.org (March 2026), CDSCO has streamlined the process for obtaining these written confirmations, reducing administrative delays for Indian API manufacturers exporting to Europe.
- Outsourcing GMP audits to QCI-certified agencies — CDSCO plans to outsource GMP audits to agencies certified by the Quality Council of India to expand inspection capacity. This reform was reported by ETPharma and Business Standard (February 2026).
- Addition of 1,500 subject matter experts — CDSCO is building a 1,500-strong scientific cadre to deepen its technical review capacity for drug applications and export certifications, as reported by IndiaMedToday (February 2026).
- Digital transformation of export certification processes — CDSCO West Zone has launched a digital transformation drive, focusing on the Online NOC-cum-Drug Export System (ONDLS) and related digital services, as reported by Pharmabiz.com (May 2026).
🌍 WHO-GMP Certification and Its Importance for Export
WHO-GMP (Good Manufacturing Practices) certification is a cornerstone of pharmaceutical export from India. The revised Schedule M of India’s Drugs and Cosmetics Act, aligned with WHO-GMP standards, was enforced from January 1, 2026, with no further extensions granted — as reported by ETPharma (December 2025) and India Today (November 2025). This means all Indian pharmaceutical manufacturers must now meet international GMP standards to maintain their manufacturing licenses.
For international buyers, WHO-GMP certification is critical because:
- Most importing countries (especially in the EU, WHO member states, and emerging markets) require WHO-GMP compliance documentation
- The COPP issued by CDSCO explicitly references the manufacturer’s GMP status
- Buyers who verify WHO-GMP certification before purchasing significantly reduce the risk of receiving substandard products
- The revised Schedule M mandates critical quality systems including: pharmaceutical quality system (PQS), validation protocols, stability testing programs, water and HVAC system qualification, and product recall procedures
✍️ The EU Written Confirmation Process: What Buyers Should Know
A significant development in India-EU pharmaceutical trade in 2026 is CDSCO’s streamlined process for issuing written confirmations for API exports to Europe. Under EU Directive 2001/83/EC, APIs imported from non-listed countries (including India) must be accompanied by a written confirmation from the exporting country’s regulatory authority, certifying that the manufacturer’s GMP standards are equivalent to those in the EU.
As reported by RAPS.org (March 2026), CDSCO has taken steps to streamline these written confirmation requests, making the process faster and more transparent. This is particularly important because:
- The EU is one of the largest importers of Indian pharmaceutical products, alongside the United States
- India-EU Free Trade Agreement (FTA) negotiations, ongoing since early 2026, are expected to further simplify pharmaceutical trade between the two regions, as reported by The Indian Express (January 2026)
- Written confirmations are typically valid for a limited period, and buyers should verify that their supplier’s confirmation is current [CITATION NEEDED]
Buyers importing European-bound pharmaceutical products from India should request a copy of the written confirmation from their supplier and verify its validity directly with CDSCO.
🔍 How International Buyers Can Verify Export Certifications
For international buyers looking to import Indian generic medicines, verifying export certifications is an essential due diligence step. Here is a practical verification framework:
- Request the CDSCO Manufacturing License — Ask your supplier for their Form 25 (manufacturing license) and Form 28 (loan license if applicable). Verify the license number and scope of manufacturing with the relevant state drug control authority.
- Ask for the WHO-GMP Certificate — Ensure the certificate is current (not expired) and covers the specific product you intend to import. Cross-check the manufacturing address on the certificate matches the supplier’s actual facility.
- Verify COPP Availability — For most regulated markets, a Certificate of Pharmaceutical Product issued by CDSCO is essential. The COPP confirms the product is approved for sale in India and manufactured to GMP standards.
- Check Inspection and Audit Records — With CDSCO outsourcing GMP audits to QCI-certified agencies, buyers should request the most recent audit report. A supplier with recent successful audits is generally more reliable.
- Work with Verified Distributors — For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory. IMSDA members are vetted for compliance with Indian pharmaceutical regulations and international trade standards.
- Request Product-Specific Documentation — For each product you plan to import, ask for the product registration certificate, analytical method validation, stability data, and batch certificate of analysis (CoA).
✅ Practical Checklist for Buyers
Use this checklist when evaluating an Indian pharmaceutical supplier for export:
- ✅ Manufacturer holds a valid CDSCO manufacturing license (Form 25) for the product category
- ✅ WHO-GMP certificate is current and covers the specific facility address
- ✅ COPP is available for the target product (essential for most regulated markets)
- ✅ EU Written Confirmation is current (for API products destined for Europe)
- ✅ Recent GMP audit report from CDSCO or QCI-certified auditor is available
- ✅ Supplier has a quality management system (PQS) in place per revised Schedule M
- ✅ Batch certificate of analysis (CoA) is provided for each shipment
- ✅ Packaging and labeling comply with importing country requirements
- ✅ Supplier is willing to provide regulatory references and customer testimonials
- ✅ Track record of exports to regulated markets (US, EU, Japan, Australia) is verifiable
🤝 Final Thoughts
India’s pharmaceutical export certification framework is evolving rapidly in 2026, with CDSCO taking significant steps to align with global regulatory standards. For international buyers, understanding this certification landscape is key to sourcing high-quality Indian generic medicines confidently. By verifying COPP, WHO-GMP, and written confirmation documents — and by working with verified distributors from the IMSDA’s verified member directory — buyers can significantly reduce compliance risk and ensure they receive genuine, high-quality pharmaceutical products.
For more information, contact IMSDA at contact@indiamedicine.org.